The agonistic CD27 mAb, varlimumab, promotes T-cell dependent tumor rejection in human CD27 transgenic mice (109), demonstrating that enhanced CD27 signaling can augment anti-tumor responses. The gene discussed is CD27; the disease is neoplasm.